

Aurora Kinase/Cdk Inhibitor - CAS 443797-96-4 - Calbiochem The Aurora Kinase/Cdk Inhibitor, also referenced under CAS 443797-96-4, controls the biological activity of Aurora Kinase/Cdk. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

Art. ID SAF-189406-5MG
Unit 1 x 5 mg
Deliverydetails No Dangerous Good

Description

A cell-permeable triazolylsulfonamido compound that acts a reversible, ATP-competitive kinase inhibitor with selectivities towards Aurora kinases (IC₅₀ = 11 and 15 nM for Aurora-A, Aurora-B, respectively) and Cdk's (IC₅₀ = 9, 4, and 3 nM for Cdk1/B, Cdk2/A, and Cdk2/E, respectively). Displays antitumor properties both in vitro (IC₅₀ in the range of 112-514 nM against various human cancer cell lines) and in a xenograft murine model in vivo (75-100 mg/kg, i.p.). A cell-permeable triazolylsulfonamido compound that acts a reversible, ATP-competitive kinase inhibitor with selectivities towards Aurora kinases (IC₅₀ = 11 and 15 nM for Aurora-A, Aurora-B, respectively) and Cdk's (IC₅₀ = 9, 4, and 3 nM for Cdk1/B, Cdk2/A, and Cdk2/E, respectively). Displays antitumor properties both in vitro (IC₅₀ in the range of 112 - 514 nM against various human cancer cell lines) and in a xenograft murine model in vivo (75-100 mg/kg, i.p.).

Text/Information	Analyte/Parameter	CAS number	Concentration/Value	Unit	Method	Source
	JNJ-7706621	[443797-96-4]				